Charles River Laboratories Intl (CRL) Stock Price, Quote & News

Company Profile

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of serv...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 781 222 6000

Website: www.criver.com

Address:

251 Ballardvale Street, Wilmington, United States

MomentumWins Jun. 20 at 5:47 PM

$CRL 250 breach needs some mojo… it got it now

0 · Reply

JarvisFlow Jun. 18 at 10:00 AM

Redburn Atlantic updates rating for Charles River ( $CRL ) to Neutral, target set at 171 → 188.

0 · Reply

swingingtech Jun. 17 at 7:13 PM

$CRL $ALGN $ENPH $FSLR https://wallstreetwaves.com/tuesdays-market-weakness-declines-in-healthcare-technology-and-communications-sectors/

0 · Reply

JarvisFlow Jun. 13 at 2:53 PM

Morgan Stanley updates rating for Charles River ( $CRL ) to Equal-Weight, target set at 225 → 220.

0 · Reply

FinJay Jun. 6 at 2:11 AM

$CRL https://youtu.be/yQKMLlDzMzM

0 · Reply

ZacksResearch Jun. 2 at 2:55 PM

$CRL extends its Huntington's partnership with CHDI Foundation — is sentiment shifting? 🤔 Following the news, shares of Charles River rose 1.1% as the collaboration is set to reach its 20th anniversary in 2025, fueling market optimism. CRL's earnings yield of 7.09% also shines against the industry’s 4.02% yield. See why this extension could boost CRL's outlook 👉 https://www.zacks.com/commentary/2480029/charles-river-stock-may-gain-from-extended-chdi-research-deal-on-hd?cid=sm-stocktwits-2-2480029-body&ADID=SYND_STOCKTWITS_TWEET_2_2480029_BODY

0 · Reply

ZacksResearch Jun. 2 at 11:15 AM

$CRL expands global reach with extended CHDI deal! The extended partnership with the CHDI Foundation promises deeper integration and global flexibility in Huntington's drug discovery. See why this could lift the stock 👉 https://www.zacks.com/stock/news/2480029/charles-river-stock-may-gain-from-extended-chdi-research-deal-on-hd?cid=sm-stocktwits-2-2480029-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2480029_TEASER

0 · Reply

FinJay May. 26 at 3:48 AM

$CRL https://youtu.be/yQKMLlDzMzM

0 · Reply

JarvisFlow May. 23 at 12:00 PM

Redburn Atlantic has adjusted their stance on Charles River ( $CRL ), setting the rating to Buy with a target price of 188 → 182.

0 · Reply

Estimize May. 19 at 1:03 PM

Wall St is expecting 2.50 EPS for $CRL Q2 [Reporting 07/30 BMO] http://www.estimize.com/intro/crl?chart=historical&metric_name=eps&utm_cont

0 · Reply

Charles River Announces Endosafe® Cartridge Recycling Program, Strengthening Sustainability Commitment

Jun 2, 2025, 8:00 AM EDT - 22 days ago

Charles River Laboratories to Present at William Blair and Jefferies Conferences

May 28, 2025, 8:00 AM EDT - 27 days ago

Charles River and CHDI Foundation Extend Multi-Decade Collaboration on Huntington's Disease Research

May 13, 2025, 8:00 AM EDT - 6 weeks ago

Charles River Laboratories to Present at Bank of America Health Care Conference

May 10, 2025, 8:49 AM EDT - 6 weeks ago

Activist Elliott reaches key agreement with Charles River. Here are three ways to create value

May 7, 2025, 5:31 PM EDT - 6 weeks ago

S&P 500 Gains & Losses Today: Stocks Gain in Volatile Session as Markets React to Fed Meeting, Trump Trade Comments

May 7, 2025, 2:46 PM EDT - 6 weeks ago

Charles River Laboratories International, Inc. (CRL) Q1 2025 Earnings Call Transcript

May 7, 2025, 12:39 PM EDT - 6 weeks ago

Charles River Laboratories' Q1 Earnings Beat Consensus, Stock Trades Higher On Signs Of Demand Stabilization

May 7, 2025, 12:17 PM EDT - 6 weeks ago

Charles River Stock Is Having Its Best Day in 13 Years. A Board Shake-Up and Business Review Will Help.

May 7, 2025, 11:56 AM EDT - 6 weeks ago

Top Stock Moves Now: Charles River Labs, Disney, Supermicro, and More

DIS SMCI

May 7, 2025, 7:35 AM EDT - 6 weeks ago

Charles River to add new directors, review business in agreement with Elliott

May 7, 2025, 7:01 AM EDT - 6 weeks ago

Charles River Laboratories Announces First-Quarter 2025 Results

May 7, 2025, 7:00 AM EDT - 6 weeks ago

Charles River Laboratories Announces Governance Updates and Strategic Review to Enhance Long-Term Stockholder Value

May 7, 2025, 6:08 AM EDT - 6 weeks ago

Exclusive: Charles River agrees with Elliott to add new directors, review business

Apr 29, 2025, 8:00 AM EDT - 2 months ago

Charles River Announces Inaugural Advanced Therapy Incubator Program Cohort

Apr 22, 2025, 8:00 AM EDT - 2 months ago

Charles River Leverages Advanced Technology to Expedite Oncology Drug Discovery and Development

Apr 15, 2025, 4:30 PM EDT - 2 months ago

Charles River Laboratories Schedules First-Quarter 2025 Earnings Release and Conference Call

Apr 11, 2025, 10:44 AM EDT - 2 months ago

What's Going On With Charles River, Certara, Simulations Plus Stocks On Friday?

CERT SLP

Mar 25, 2025, 8:00 AM EDT - 3 months ago

Charles River and Valo Health Identify a Potential Therapeutic for Lupus Using Logica®, an AI-Powered Drug Discovery Platform

Mar 11, 2025, 8:00 AM EDT - 3 months ago

Charles River Laboratories to Present at Barclays Global Healthcare Conference

Mar 4, 2025, 4:05 AM EST - 4 months ago

FairJourney Biologics Acquires Charles River Laboratories South San Francisco Facility

Feb 25, 2025, 8:00 AM EST - 4 months ago

Charles River Announces Agreement with Singapore General Hospital

Feb 19, 2025, 4:58 PM EST - 4 months ago

Analyst Sees Charles River As Preclinical Leader But Maintains Neutral Stance

Feb 19, 2025, 3:03 PM EST - 4 months ago

Charles River Laboratories International, Inc. (CRL) Q4 2024 Earnings Call Transcript

Feb 19, 2025, 8:11 AM EST - 4 months ago

Charles River beats quarterly estimates on stable demand for drug development services

Feb 19, 2025, 7:00 AM EST - 4 months ago

Charles River Laboratories Announces Fourth-Quarter and Full-Year 2024 Results and Provides 2025 Guidance

Feb 11, 2025, 8:00 AM EST - 4 months ago

Charles River and Deciphex Extend Global Partnership to Expand Digital Pathology Offering with Exclusive Image Management Solutions

Jan 28, 2025, 4:30 PM EST - 5 months ago

Charles River Laboratories Schedules Fourth-Quarter 2024 Earnings and 2025 Guidance Release and Conference Call

Jan 21, 2025, 8:00 AM EST - 5 months ago

Charles River Expands Apollo™ Ecosystem, Offering Bespoke Client Experiences

Jan 16, 2025, 8:00 AM EST - 5 months ago

Charles River and Akron Bio Announce Collaboration to Enhance Operations with Integration of CGMP Materials into Cell Therapy Platform

Jan 13, 2025, 8:00 AM EST - 5 months ago

Charles River Laboratories to Present at J.P. Morgan Healthcare Conference

Jan 7, 2025, 8:00 AM EST - 6 months ago

Deciphex Secures $32.3M Series C to Address Global Pathology Shortage

Dec 20, 2024, 7:51 AM EST - 6 months ago

Tax-related selling is hitting these 7 stocks — but their loss could be your gain

AVNW CVS DLHC FL VAL

Dec 5, 2024, 8:00 AM EST - 7 months ago

Charles River Introduces Global Biotech Incubator Program

Dec 2, 2024, 8:00 AM EST - 7 months ago

Charles River Laboratories to Present at Evercore ISI Investor Conference

Nov 11, 2024, 8:00 AM EST - 8 months ago

Charles River Laboratories to Present at UBS and Jefferies Conferences

Nov 6, 2024, 6:51 PM EST - 8 months ago

Charles River Laboratories International, Inc. (CRL) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 8:30 AM EST - 8 months ago

Charles River Laboratories raises annual profit forecast on stabilizing biotech demand

Nov 6, 2024, 7:00 AM EST - 8 months ago

Charles River Laboratories Announces Third-Quarter 2024 Results

Oct 17, 2024, 8:00 AM EDT - 8 months ago

Charles River Launches New Retrogenix® Non-Human Protein Library

Oct 16, 2024, 4:30 PM EDT - 8 months ago

Charles River Laboratories Schedules Third-Quarter 2024 Earnings Release and Conference Call

Oct 8, 2024, 11:26 AM EDT - 9 months ago

Operadora de Fondos Banorte Adopts Charles River's Cloud-Based Platform

Oct 3, 2024, 8:00 AM EDT - 9 months ago

Charles River Provides Translational Expertise at Neuroscience 2024

Oct 2, 2024, 8:00 AM EDT - 9 months ago

Charles River and Lundbeck Enter Agreement Utilizing AI-Powered Logica® to Advance the Discovery of Novel Drugs for Neurological Disease

Sep 19, 2024, 6:00 AM EDT - 9 months ago

Xspray Pharma Announces Positive FDA Meeting and Plans for Dasynoc NDA Resubmission

Sep 18, 2024, 8:30 AM EDT - 9 months ago

Ori Biotech and Charles River Laboratories Collaborate to Accelerate Life-Saving Cell and Gene Therapy Development and Manufacturing

Sep 17, 2024, 8:00 AM EDT - 10 months ago

Charles River Laboratories and CEBINA Announce Strategic Collaboration to Accelerate Cutting Edge Neuroscience Research

Sep 4, 2024, 8:00 AM EDT - 10 months ago

Charles River and Insightec Announce Strategic Collaboration to Advance Therapeutic Development Utilizing Focused Ultrasound in Neuroscience

Sep 3, 2024, 4:30 PM EDT - 10 months ago

Charles River Laboratories to Present at Baird and Morgan Stanley Conferences

MomentumWins Jun. 20 at 5:47 PM

$CRL 250 breach needs some mojo… it got it now

0 · Reply

JarvisFlow Jun. 18 at 10:00 AM

Redburn Atlantic updates rating for Charles River ( $CRL ) to Neutral, target set at 171 → 188.

0 · Reply

swingingtech Jun. 17 at 7:13 PM

$CRL $ALGN $ENPH $FSLR https://wallstreetwaves.com/tuesdays-market-weakness-declines-in-healthcare-technology-and-communications-sectors/

0 · Reply

JarvisFlow Jun. 13 at 2:53 PM

Morgan Stanley updates rating for Charles River ( $CRL ) to Equal-Weight, target set at 225 → 220.

0 · Reply

FinJay Jun. 6 at 2:11 AM

$CRL https://youtu.be/yQKMLlDzMzM

0 · Reply

ZacksResearch Jun. 2 at 2:55 PM

0 · Reply

ZacksResearch Jun. 2 at 11:15 AM

0 · Reply

FinJay May. 26 at 3:48 AM

$CRL https://youtu.be/yQKMLlDzMzM

0 · Reply

JarvisFlow May. 23 at 12:00 PM

Redburn Atlantic has adjusted their stance on Charles River ( $CRL ), setting the rating to Buy with a target price of 188 → 182.

0 · Reply

Estimize May. 19 at 1:03 PM

Wall St is expecting 2.50 EPS for $CRL Q2 [Reporting 07/30 BMO] http://www.estimize.com/intro/crl?chart=historical&metric_name=eps&utm_cont

0 · Reply

Armonica423 May. 10 at 10:00 PM

$CRL Big exposure for CYDY at 3 oncology conferences this next week, do your dd research

0 · Reply

TheDayTradingAcademy May. 8 at 2:44 PM

The U.S. pharmaceutical company $CRL soared +18.68% on Wednesday at $136.97 & another 3% late morning Thursday at $141.10, after lifting its full-year earnings guidance. Charles River now anticipates its adjusted earnings will range from $9.30 to $9.80 per share, compared to its earlier call for $9.10 to $9.60 a share. The stock is up +41.13% in the past month, but still down -23.59% in 2025 & -38.69% y/y, with a market cap of $6.73B.

0 · Reply

JarvisFlow May. 8 at 1:00 PM

Baird has updated their rating for Charles River ( $CRL ) to Neutral with a price target of 140.

0 · Reply

KabilSamir May. 8 at 10:18 AM

$PPCBD $AVDX $OPAL $CRL $PHIO

0 · Reply

ivychand May. 7 at 5:32 PM

$CRL Recently stumbled across an app called stockburger.app — wasn’t expecting much, but gave it a shot. Here’s what stood out so far: ✅ Early alerts on meme stock momentum — pulls from Reddit, Twitter, Discord, etc. ✅ Spikes in attention — flags tickers that are suddenly trending ✅ AI filtering — cuts out junk and focuses on meaningful chatter ✅ Community strength metrics — shows where the hype is coming from ✅ Custom filters — track keywords, sectors, or specific tickers Honestly? Looks promising if you’re into pre-market movers or momentum trades. Been surprisingly useful for spotting action before it hits scanners. Just sharing some personal observations from the past couple days — got an alert, and shortly after, the price took off hard. Pretty impressive follow-through

0 · Reply

damorphius May. 7 at 2:08 PM

$CRL Summary: Bullish Thesis 📌 Why Bulls Like CRL: Strong recovery potential after an overdone selloff Industry leadership in essential R&D services Raised full-year guidance and positive margin outlook Undervalued on historical P/E and intrinsic value Optionality from activist involvement and strategic review 🎯 Long-Term Price Target: $175 (12–18 months) 🎯 Realistic Short-Term Target: $150–160 (3–6 months)

0 · Reply

damorphius May. 7 at 2:08 PM

$CRL Institutional Confidence High insider and institutional ownership indicates long-term belief in fundamentals. Recent activist involvement (Elliott Investment Management) could unlock shareholder value through business optimization or asset sales.

0 · Reply

damorphius May. 7 at 2:07 PM

$CRL Secular Tailwinds Global R&D spending is expected to rebound in late 2025, aided by AI-driven drug discovery and expanding biologics research. CRL's early-stage services are mission-critical to biotech, making it a long-term winner regardless of near-term pharma slowdowns.

0 · Reply

damorphius May. 7 at 2:07 PM

$CRL Valuation Discount After Selloff CRL is down ~37% YTD and recently rebounded +18% on earnings news. Current Price (May 7): $136 Forward P/E: ~13.2x vs. 5-year average of ~19x → suggests undervaluation.

0 · Reply

damorphius May. 7 at 2:07 PM

$CRL Earnings Stability & Strategic Adjustments Q1 2025 revenue: $984.2M (down 2.7% YoY) but beat analyst expectations. Adjusted EPS: $2.27 vs. $2.05 consensus. Despite lower GAAP income, adjusted earnings outperformed, reflecting effective cost control. The company raised FY2025 EPS guidance to $9.90–$10.40 (from $9.70–$10.20), showing management confidence.

0 · Reply

damorphius May. 7 at 2:07 PM

$CRL Strong Market Position in Drug Development Services Charles River is a global leader in outsourced preclinical and clinical laboratory services, which are essential for drug discovery and safety testing. Their diverse client base includes major pharmaceutical and biotech firms, academic institutions, and government agencies—providing revenue stability.

0 · Reply

TulipmaniaJHH May. 7 at 1:31 PM

$CRL gonna get smacked in Q2 / Q3 lol, I hope not but it’s inevitable

0 · Reply

Market Cap	7.24B
Revenue (ttm)	4.05B
Net Income (ttm)	22.20M
EPS (ttm)	N/A
PE Ratio	14.19
Forward PE	15.33
Profit Margin	0.55%
Debt to Equity Ratio	0.78

Volume	823,800
Avg Vol	1,554,620
Day's Range	N/A - N/A
Shares Out	49.12M
Stochastic %K	47%
Beta	1.48
Analysts	Sell
Price Target	$158.64